Artificial blood substitute

Emissions of remedies

Full list of emissions of pharmaceuticals and curative plants: Actovegin, Allergy treatment, Arbidol, Deltaran, Dilacor, Esentiale, Fosamax, Liver treatment, Noni, Prednisolone, Preductal, Samprost, Soursop, Ursosan, Weight loss complex.


AT 300 – working title of the “Artificial Blood substitute” project.

Authors of the invention: Irina Kuznetsova, PhD Biology, Master’s Degree in Chemical Sciences, and Evgeny Maevsky, PhD Medicine. AT 300 was developed in the Russian Scientific-Research Institute of Hematology and Transfusion Medicine, St. Petersburg.

Dr. Kuznetsova and Dr. Maevsky participated in the creation of the Russian pharmaceutical – artificial blood substitute – Perftoran, developed on the basis of perfluoro-organic compounds of medical application. Evgeny Maevsky developed the manufacturing technology of Perftoran emulsion and methods of Perftoran medical application.

Artificial blood substitute Perftoran had been under development for 17 years: from1980 to 1997. In 1997 Perftoran was registered and approved in Russia for clinical application in Medicine.

AT 300 – is the new generation of Perftoran. The emulsion was created on the basis of perfluoro-organic compounds, thanks to the experience gained during Perftoran application. Development of technological methods and principles resulted in obtaining stable emulsions. AT 300, unlike Perftoran, does not need to be stored at low temperatures and is sterilized as a finished dosage form (FDF).

The stable emulsion obtained is based on perfluoro-carbons (PFC) and phospholipids (PL). AT 300 fully complies with international GLP requirements for the preparation of intravenous injections. Laboratory samples of emulsion in a closed bottle are able to withstand heat sterilization and retain particles size (~ 100 nm) for 1 year, provided they are stored under the conditions stipulated for storage at the temperature of ~ + 4° С.

Besides that, PFC nanoparticles retain their structure for the named period of observation, as the surface properties of the obtained particles do not change in the process of storage.

AT 300 emulsion and its production method are patented (PCT/RU2005/000058, WO2005/089739 A1). An American patent No. US 7,842,730 B2 dated November 30, 2010 and a Chinese patent No. CN 101014326 dated September 1, 2010 have been issued. Patenting of AT 300 is still in progress in Europe, India and Japan.

All the components of emulsion (raw materials) are allowed for application in medicine and pharmacology.  

  • Emission

    The essence of the “Emission” project is the possibility to transmit emission (properties) of organic and inorganic substances and biological objects remotely via communication lines using Internet addressing system.

  • Artificial Blood Substitute

    Authors of the invention: Ph.D. Biology, Candidate of Chemical Sciences, Kuznetsova Irina and Ph.D. Medicine Evgeny Maevsky. AT300 was developed on the basis of the Russian Scientific-Research Institute of Hematology and Transfusion Medicine, St. Petersburg.

  • Cancer treatment

    Dissymetric therapy (anisotropizing) tinctorial therapy (DST) – is an innovative method of oncological diseases treatment. It is based on the theory of Professor Kutushov about the causes of cancer and it's development.